Evidence map›Paper›PMID 35951676›Full record

ArticlePLoS pathogens2022

Localization and functions of native and eGFP-tagged capsid proteins in HIV-1 particles.

Ashwanth C Francis, Anna Cereseto, Parmit K Singh, Jiong Shi, Eric Poeschla, Alan N Engelman, Christopher Aiken, Gregory B Melikyan

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Lenacapavir disrupts HIV-1 core integrity while stabilizing the capsid lattice.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Capsid-host interactions for HIV-1 ingress.Microbiology and molecular biology reviews : MMBR · 2023
    Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 2 countries.

Ashwanth C FrancisInstitute of Molecular Biophysics, Department of Biological Sciences, Florida State University, Tallahassee, Florida, United States of America.ORCID 0000-0002-8663-2038
Anna CeresetoCenter for Integrative Biology (CIBIO), University of Trento, Trento, Italy.
Parmit K SinghDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
Jiong ShiDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Eric PoeschlaDivision of Infectious Diseases, University of Colorado Denver, Denver, Colorado, United States of America.
Alan N EngelmanDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
Christopher AikenDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Gregory B MelikyanDivision of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America.ORCID 0000-0001-5385-3013
Harvard University · USVanderbilt University Medical Center · USEmory University · USFlorida State University · USUniversity of Colorado Denver · USUniversity of Trento · IT

Funding

X-ray Crystallographic Fragment Screening CoreU54AI150472 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI OLSON, ARTHUR J. · 2019 to 2021
$15.7M
Technology Development 2: MAS NMR and dynamic nuclear polarization for HIV-1 structural biologyP50AI150481 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GRONENBORN, ANGELA M. · 2019 to 2021
$14.1M
Nuclear Localization of HIV-1 Preintegration ComplexesR01AI052014 · NIAID · DANA-FARBER CANCER INSTITUTE · PI ENGELMAN, ALAN N. · 2003 to 2025
$11.4M
Imaging of Single HIV-1 Uncoating and Transport to the nucleusR01AI129862 · NIAID · EMORY UNIVERSITY · PI KVARATSKHELIA, MAMUKA, MELIKIAN, GREGORY B · 2017 to 2025
$5.4M
Novel Approaches to Innate Immunity Against HIV-1 and Other Co-infection VirusesDP1DA043915 · NIDA · UNIVERSITY OF COLORADO DENVER · PI POESCHLA, ERIC M. · 2017 to 2021
$3.9M
Delineating a role for CA in HIV-1 nuclear transport to sites of integrationR21AI145541 · NIAID · FLORIDA STATE UNIVERSITY · PI FRANCIS, ASHWANTH CHRISTOPHER · 2020 to 2021
$426k
NIAID NIH HHS P50 AI150481NIAID NIH HHS R01 AI052014NIAID NIH HHS R01 AI129862NIAID NIH HHS R21 AI145541NIAID NIH HHS U54 AI150472NIDA NIH HHS DP1 DA043915
6 · The paper itself

Abstract

In infectious HIV-1 particles, the capsid protein (CA) forms a cone-shaped shell called the capsid, which encases the viral ribonucleoprotein complex (vRNP). Following cellular entry, the capsid is disassembled through a poorly understood process referred to as uncoating, which is required to release the reverse transcribed HIV-1 genome for integration into host chromatin. Whereas single virus imaging using indirect CA labeling techniques suggested uncoating to occur in the cytoplasm or at the nuclear pore, a recent study using eGFP-tagged CA reported uncoating in the nucleus. To delineate the HIV-1 uncoating site, we investigated the mechanism of eGFP-tagged CA incorporation into capsids and the utility of this fluorescent marker for visualizing HIV-1 uncoating. We find that virion incorporated eGFP-tagged CA is effectively excluded from the capsid shell, and that a subset of the tagged CA is vRNP associated. These results thus imply that eGFP-tagged CA is not a direct marker for capsid uncoating. We further show that native CA co-immunoprecipitates with vRNP components, providing a basis for retention of eGFP-tagged and untagged CA by sub-viral complexes in the nucleus. Moreover, we find that functional viral replication complexes become accessible to integrase-interacting host factors at the nuclear pore, leading to inhibition of infection and demonstrating capsid permeabilization prior to nuclear import. Finally, we find that HIV-1 cores containing a mixture of wild-type and mutant CA interact differently with cytoplasmic versus nuclear pools of the CA-binding host cofactor CPSF6. Our results suggest that capsid remodeling (including a loss of capsid integrity) is the predominant pathway for HIV-1 nuclear entry and provide new insights into the mechanism of CA retention in the nucleus via interaction with vRNP components.

Indexed as

HIV-1HIV InfectionsActive Transport, Cell NucleusCapsidCapsid ProteinsHumansVirionVirus IntegrationVirus ReplicationVirus UncoatingCapsid Proteins

Identifiers

PMID35951676
PMCPMC9426931
OpenAlexW4291020250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.